Luke Riggan
Immunologist and investor focused on in vivo cell therapies
San Francisco, California
Joined June 2026
Network
2K connectionsBGXWRE
JEEQLC
EHSDDB
NCFSMC
MDVAGS
NTMC
HDMR
Summary
Translational immunology researcher with a focus on NK cell biology and gene-based cell engineering. nih+2
Scientist-entrepreneur who co-founded and led ImmunoVec's cell therapy efforts, advancing an in vivo nanoparticle DNA-delivery platform and securing ARPA-H EMBODY funding. immunovec+2
Now moving into early-stage investing and industry strategy, engaging with immune-engineering startups and broader biotech investing at Amplify Partners. amplifypartners+1
Committed mentor and educator: has mentored students, taught undergraduate courses, and listed as a mentor on educational platforms. osullivanlab+1
Work
Education
Projects
Writing
Author Correction: MEF2C regulates NK cell effector functions through control of lipid metabolism
April 1, 2024Correction notice (Nature Immunology) listing authors including Luke Riggan; related to work on MEF2C's role in NK cell effector function and lipid metabolism.
The transcription factor Fli1 restricts the formation of memory precursor NK cells during viral infection
January 1, 2022Research article identifying transcriptional and epigenetic NK effector states and demonstrating that Fli1 limits memory-precursor NK cell formation via regulation of pro-apoptotic pathways; uses single-cell RNA-seq and functional studies in mouse MCMV infection.
Arrested development: suppression of NK cell function in the tumor microenvironment
January 1, 2021Review summarizing mechanisms that impair NK cell recruitment and function within solid tumor microenvironments and discussing strategies to enhance adoptive NK cell therapies and overcome intrinsic/extrinsic checkpoints.